Skip to main content
. 2021 Dec 30;57(4):568–574. doi: 10.1177/00185787211066460

Table 1.

Demographics and Baseline Characteristics of the Study Sample.

Characteristic Cefoxitin (n = 30) Ertapenem (n = 55) P value
Gender (%) .11
 Female 40 (12) 58.1 (32)
Age (mean ± SD) years 68.03 ± 18.26 74.82 ± 12.798 .049
BMI (mean ± SD) 28.58 ± 5.51 28.82 ± 6.76 .87
DM (%) 63.33 (19) 74.55 (41) .28
CAD (%) 20 (6) 18.18 (10) .84
Hypertension (%) 53.33 (16) 81.82 (45) .0068
Dyslipidemia (%) 53.33 (16) 60 (33) .55
Liver disease (%) 13.33 (4) 12.73 (7) .94
Cerebrovascular accident (%) 36.67 (11) 10.91 (6) .0069
COPD (%) 10 (3) 25.45 (14) .1
CHF (%) 26.67 (8) 21.82 (12) .62
Mechanically ventilated (%) 13.33 (4) 3.64 (2) .12
Renal function .225
 Normal renal function (%) 43 (13) 50.9 (28)
 Acute kidney injury (%) 13.3 (4) 5.4 (3)
 Chronic kidney disease (%) 30 (9) 40 (22)
 Acute on of chronic kidney disease (%) 10 (3) 0.36 (2)
 End stage kidney disease (%) 3.3 (1) 0
Chronic respiratory failure (%) 20 (6) 7.27 (4) .09
Foley catheter at time of infection (%) 63.3 (19) 42 (23) .077
Organism in first culture .686
E. coli (%) 56.6 (17) 60 (33)
Klebsiella spp. (%) 43.3 (13) 36.3 (20)
 Both E. coli and Klebsiella spp. (%) 0 3.6 (2)
Concomitant antibiotic (%) 6.7 (2) 0 .122
Charlson Comorbidity Index (mean ± SD) 5.87 ± 2.56 6.53 ± 2.58 .26
Antibiotic dose in gram (mean ± SD) 1.433 ± 0.5 1.01 ± 0.36 NA
Frequency in hour (mean ± SD) 9.73 ± 5.53 23.93 ± 4.25 NA
WBC at therapy initiation × 109/L (mean ± SD) 12.96 ± 5.17 11.32 ± 5.92 .21
Temperature at therapy initiation ℃ (mean ± SD) 37.33 ± 0.73 37.32 ± 1.07 .95
CRP at therapy initiation in mg/L (mean ± SD) 52.09 ± 59.86 87.79 ± 80.12 .08
Procalcitonin at therapy initiation in ng/mL (mean ± SD) 0.1648 ± 0.16 0.19 ± 0.33 .75

Note. BMI = Body Mass Index; CAD = coronary artery disease; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein; DM = diabetes mellitus.